Lipid-lowering effect of monascus garlic fermented extract (MGFE) in hyperlipidemic subjects

Hiroshima Journal of Medical Sciences

Volumn 55, Issue 2, 2006, Pages 59-64

  Sumioka, Isao ^a   Hayama, Minoru ^a   Shimokawa, Yoshiyuki ^a   Shiraishi, Sumihiro ^a   Tokunaga, Akira ^b  

^a WAKUNAGA PHARMACEUTICAL CO LTD   (Japan)

^b Tokunaga Clinic   (Japan)

Author keywords

Arteriosclerosis; Cholesterol; Garlic; Hyperlipidemia; Monascus pilosus

Indexed keywords

CHOLESTEROL; GARLIC EXTRACT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID PEROXIDE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 2; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN BLOOD LEVEL; MALE; MONASCUS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

ADULT; FEMALE; FERMENTATION; GARLIC; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; MALE; MIDDLE AGED; MONASCUS; PLANT EXTRACTS; TRIGLYCERIDES;

EID: 33746227530     PISSN: 00182052     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Anderson, T.J., Meredith, I.T., Yeung, A.C., Frei, B., Selwyn, A.P. and Ganz, P. 1995. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N. Engl. J. Med. 332: 488-493.
2. Aniya, Y., Ohtani, I.I., Higa, T., Miyagi, C., Gibo, H., Shimabukuro, M., Nakanishi, H. and Taira, J. 2000. Dimerumic acid as an antioxidant of the mold, Monascus anka. Free. Radic. Biol. Med. 28: 999-1004.
3. Austin, M.A., Hokanson, J.E. and Edwards, K.L. 1998. Hypertriglyceridemia as a cardiovascular risk factor. Am. J. Cardiol. 81: 7B-12B.
4. Cambien, F., Jacqueson, A., Richard, J.L., Warnet, J.M., Ducimetiere, P. and Claude, J.R. 1986. Is the level of serum triglyceride a significant predictor of coronary death in "normocholesterolemic" subjects? The Paris Prospective Study. Am. J. Epidemiol. 124: 624-632.
5. Davies, M.J., Richardson, P.D., Woolf, N., Katz, D.R. and Mann, J. 1993. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. 69:377-381.
6. Dieber-Rotheneder, M., Puhl, H., Waeg, G., Striegl, G. and Esterbauer, H. 1991. Effects of oral supplementation with D-α-tocopherol on the vitamin E content of human low density lipoproteins and resistance to oxidation. J. Lipid Res. 32: 1325-1332.
7. Downs, J.R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D.R., Beere, P.A., Langendorfer, A., Stein, E.A., Kruyer, W. and Getto, A.M. Jr. 1998. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 279:1615-1622.
8. Endo, A. 1980. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Antibiot. (Tokyo) 33: 334-336.
9. Germershausen, J.I., Hunt, V.M., Bostedor, R.G., Bailey, P.J., Karkas, J.D. and Alberts, A.W. 1989. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 158: 667-675.
10. Goldstein, J.L. and Brown, M.S. 1990. Regulation of the mevalonate pathway. Nature 343: 425-430.
11. Grundy, S.M. 1988. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24-33.
12. Hafidh, S., Senkottaiyan, N., Villarreal, D. and Alpert, M.A. 2005. Management of the Metabolic Syndrome. Am. J. Med. Sci. 330: 343-351.
13. Havel, R.J., Hunninghake, D.B., Illingworth, D.R., Lees, R.S., Stein, E.A., Tobert, JA., Bacon, S.R., Bolognese, J.A., Frost, P.H., Lamkin, G.E., Lees, A.M., Leon, A.S., Gardner, K., Johnson, G., Mellies, M.J., Rhymer, P.A. and Tun, P. 1987. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann. Intern. Med. 107: 609-615.
14. Hoeg, J.M., Maher, M.B., Bailey, K.R. and Brewer, H.B.Jr. 1986. The effects of mevinolin and neomycin alone and in combination on plasma lipid and lipoprotein concentrations in type II hyperlipoproteinemia. Atherosclerosis. 60: 209-214.
15. Hoeg, J.M., Maher, M.B., Zech, L.A., Bailey, K.R., Gregg, R.E., Lackner, K.J., Fojo, S.S., Anchors, MA., Bojanovski, M., Sprecher, D.L. and Brewer, H.B.Jr. 1986. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am. J. Cardiol. 57: 933-939.
16. Hoeg, J.M. and Brewer, H.B. Jr. 1987. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA. 258: 3532-3536.
17. Iizuka, H. and Lin, C.F. 1981. On the genus Monascus of Asia and its specific characteristics. Adv. Biotech. 2: 555-561.
18. Illingworth, D.R. 1984. Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia. Ann. Intern. Med. 101: 598-604.
19. Iso, H., Naito, Y., Sato, S., Kitamura, A., Okamura, T., Sankai, T., Shimamoto, T., Iida, M. and Komachi, Y. 2001. Serum triglycerides and risk of coronary heart disease among Japanese men and women. Am. J. Epidemiol. 153: 490-499.
20. Jeppesen, J., Hein, H.O., Suadicani, P. and Gyntelberg, F. 1998. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 97: 1029-1036.
21. Kannnel, W.B., Castelli, W.P. and Gordon, T. 1979. Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med. 90: 85-91.
22. Kita, T., Nagano, Y., Yokode, M., Ishii, K., Kume, N., Ooshima, A., Yoshida, H. and Kawai, C. 1987. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84: 5928-5931.
23. Leslie, B.R. 2005. Metabolic syndrome: historical perspectives. Am. J. Med. Sci. 330: 264-268.
24. Martinkova, L., Juzlova, P. and Vesely, D. 1995. Biological activity of polyketide pigments produced by fungus Monascus. J. Appl. Bacteriol., 79: 609-606.
25. Matsuzawa, Y., Itakura, H., Kita, T., Mabuchi, H., Matsuzaki, M., Nakaya, N., Oikawa, S., Saito, Y., Sasaki, J., Shimamoto, K. and the J-LIT Group. 2000. Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: The Japan Lipid Intervention Trial (J-LIT). Curr. Ther. Res. 61: 219-243.
26. Menuet, R., Lavie, C.J. and Milani, R.V. 2005. Importance and management of dyslipidemia in the metabolic syndrome. Am. J. Med. Sci. 330: 295-302.
27. Ohara, Y., Peterson, T.E. and Harrison, D.G. 1993. Hypercholesterolemia increases endothelial superoxide anion production. J. Clin. Invest. 91: 2546-2551.
28. Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., Macfarlane, P.W., McKillop, J.H. and Packard, C.J. 1995. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333: 1301-1307.
29. Stander, J., Wentworth, D. and Neaton, J.D. 1986. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA. 256: 2823-2828.
30. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. and Witztum, J.L. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320: 915-924.
31. Steinbrecher, U.P., Lougheed, M., Kwan, W.C. and Dirks, M. 1989. Recognition of oxidized low density lipoprotein by the scavenger receptor of macrophages results from derivatization of apolipoprotein B by products of fatty acid peroxidation. J. Biol. Chem. 264:15216-15223.
32. Sumioka, I., Yasuda, K., Kashimoto, N., Ushijima, M., Moriguchi, T. and Kyo, E. 2003. Monascus garlic fermented extract, a unique fermented material, reduces the development of hyperlipidemia and atherosclerotic lesions in cholesterol-fed rabbits. Oyo Yakuri/Pharmacometrics 65: 51-59.
33. Taira, J., Miyagi, C. and Aniya, Y. 2002. Dimerumic acid as an antioxidant from the mold, Monascus anka: the inhibition mechanisms against lipid peroxidation and hemeprotein-mediated oxidation. Biochem. Pharmacol. 63:1019-1026.
34. The Lovastatin Study Group II. 1986. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA. 256: 2829-2834.
35. The lovastatin study group IV. 1990. A multicenter comparison of lovastatin and probcol for treatment of severe primary hypercholesterolemia. Am. J. Cardiol. 66: 22B-30B.
36. Vega, G.L. and Grundy, S.M. 1990. Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy. JAMA. 264: 2759-2763.
37. Watanabe, T., Yamamoto, A., Nagai, S. and Terabe, S. 1997. Separation and determination of Monascus yellow pigments for food by micellar electrokinetic chromatography. Anal. Sci. 13: 571-575.
38. Williams, R.J., Motteram, J.M., Sharp, C.H. and Gallagher, P.J. 1992. Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis. 94:153-159.
39. Wong, H.C. and Koehler, P. 1981. Production and isolation of an antibiotic from Monascus purpureus and its relationship to pigment production. J. Food Sci. 46: 589-592.
40. Yano, Y., Irie, N., Homma, Y., Tsushima, M. Takeuchi, I., Nakaya, N. and Goto, Y. 1980. High density lipoprotein cholesterol levels in the Japanese. Atherosclerosis. 36: 173-181.